Capper Joseph H 4

What Happened
Joseph H. Capper, a director of Anika Therapeutics, was granted 10,402 restricted stock units (RSUs) on June 18, 2026. The Form 4 reports the acquisition at $0.00 per share (standard for awards), so no cash was paid; the Form 4 entry lists a reported value of $0. This is a compensation award (code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-18 — Form 4 filed: 2026-06-23 (appears to be outside the standard 2-business-day reporting window). Accession: 0001193125-26-279539.
• Security/amount: 10,402 RSUs granted; reported price: $0.00; reported transaction value: $0.
• Shares owned after transaction: not specified in the provided data.
• Footnote: Each RSU is a contingent right to one common share; the RSUs vest in full on the earlier of the 2027 annual meeting or June 18, 2027.
• Transaction code: A (award/grant).

Context
RSUs are a form of equity compensation that convert to shares upon vesting; they do not represent immediately purchasable stock and are commonly used for director and executive pay. Because this is a grant (not a purchase or sale), it should be viewed as compensation disclosure rather than a direct signal of the insider buying or selling stock. The filing date suggests the Form 4 was submitted after the typical 2-business-day window for reporting—which is relevant for timeliness but does not change the nature of the award.